P/E at 33.46 vs Industry's 32.43: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Parity

Sun Pharmaceutical Industries Ltd trades at a P/E of 33.46, slightly above the Pharmaceuticals & Biotechnology industry average of 32.43. This 3.2% premium suggests investors are willing to pay a bit more for the stock relative to its peers, reflecting expectations of either superior earnings quality or growth prospects. However, the premium is not excessive, indicating a valuation that remains broadly in line with sector norms. The market capitalisation of Rs 4,06,243 crores places it firmly in the large-cap category, underscoring its significance within the sector. Sun Pharmaceutical Industries Ltd’s P/E ratio invites the question: previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? The valuation premium is a key factor in this reassessment.

Performance Across Timeframes: Divergent Momentum

The stock’s performance over the past year has been negative, with a return of -3.68%, underperforming the Sensex’s -0.57% by 3.11 percentage points. This underperformance contrasts with the three-month period, where Sun Pharmaceutical Industries Ltd posted a modest gain of 1.09%, outperforming the Sensex’s decline of -6.54%. This divergence suggests a recent shift in momentum, possibly reflecting short-term catalysts or sector rotation. However, the one-month return of -6.02% versus the Sensex’s 2.68% gain indicates volatility and mixed signals in the near term. Year-to-date, the stock has declined by 1.88%, outperforming the Sensex’s sharper fall of 8.34%, which may hint at relative resilience despite broader market pressures. Is this recent momentum sustainable or a temporary reprieve?

Moving Average Configuration: Signs of a Tentative Recovery

The technical picture for Sun Pharmaceutical Industries Ltd reveals a nuanced trend. The stock is trading above its 5-day moving average but remains below the 20-day, 50-day, 100-day, and 200-day moving averages. This configuration typically indicates a short-term bounce within a longer-term downtrend or consolidation phase. The fact that the stock has not yet breached the longer-term moving averages suggests that the recovery is tentative and may face resistance ahead. The 5-day average support could be a base for further attempts to regain lost ground, but the broader trend remains under pressure. The 1.98% gain over the past week, outperforming the Sensex’s 0.72%, aligns with this short-term positive momentum. Is this a genuine recovery or a dead-cat bounce? The moving average configuration provides the clearest answer.

Relative Performance: Long-Term Strength Amid Recent Challenges

Examining longer-term returns, Sun Pharmaceutical Industries Ltd has delivered robust gains. Over three years, the stock has appreciated by 69.10%, more than double the Sensex’s 30.38% return. The five-year performance is even more striking, with a 161.19% gain compared to the Sensex’s 59.95%. However, the ten-year return of 102.88% trails the Sensex’s 204.79%, reflecting a period of relative underperformance in the distant past. These figures highlight the stock’s capacity for strong medium-term growth despite recent volatility. The mixed short-term returns juxtaposed with solid multi-year gains raise the question: should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Sector Context: Pharmaceuticals & Biotechnology Performance Snapshot

The Pharmaceuticals & Biotechnology sector has experienced a mixed performance landscape recently. While some stocks have posted gains, others have faced headwinds due to regulatory pressures and global supply chain disruptions. Sun Pharmaceutical Industries Ltd’s performance aligns with this sector variability, showing resilience in certain periods and weakness in others. The sector’s average P/E of 32.43 reflects moderate valuation levels, with Sun Pharmaceutical Industries Ltd’s slight premium indicating investor confidence relative to peers. The sector’s mixed results underscore the importance of analysing individual stock data rather than relying solely on broad sector trends.

Rating Context: Previously Hold, Now Reassessed

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as Hold. The rating was updated on 23 Feb 2026, reflecting changes in the company’s valuation, performance, and technical indicators. The reassessment considers the stock’s current P/E premium, recent momentum shifts, and moving average configuration. This comprehensive four-parameter analysis factors in valuation, price action, sector context, and historical returns — what is the current rating for Sun Pharmaceutical Industries Ltd?

Conclusion: A Complex Data Story

The data for Sun Pharmaceutical Industries Ltd paints a nuanced picture. Its valuation premium over the industry is modest, suggesting measured investor optimism. Performance metrics reveal a stock that has struggled over the past year but shows signs of short-term recovery, supported by a moving average configuration indicating a tentative bounce. Long-term returns remain strong, highlighting the company’s resilience over multiple years despite recent volatility. The sector’s mixed results add further complexity to the analysis. The updated rating, following a previous Hold, reflects these multifaceted factors — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today